116 results about "Bile duct cancer" patented technology

The present invention relates to a method aiding in the assessment of cancer. It discloses the use of the proapoptotic caspase adaptor protein (=PACAP) as a universal marker of different types of cancer. PACAP aids in the assessment of pulmonary or lung cancer (LC), particularly of non-small cell lung carcinoma (NSCLC), but also of other specific types of cancer. Such specific types of cancer are e.g. colon, bladder, cervix, ovary, endometrial, head and neck, breast, melanoma, pancreas, kidney, prostate, esophagus, stomach or bile duct cancer. Furthermore, the present invention especially relates to a method for assessing cancer from a liquid sample, derived from an individual by measuring PACAP in said sample. Measurement of PACAP can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.

The present invention provides antibodies useful as therapeutics for treating and / or preventing diseases associated with cells expressing CLDN6, including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.

The present invention relates to a method aiding in the assessment of cancer. It discloses the use of the human fibroblast activation protein (FAP / seprase) as a universal marker of different cancer types. Seprase aids in the assessment of pulmonary or lung cancer (LC) or of colon cancer, e.g., of non-small cell lung carcinoma (NSCLC) or colorectal cancer (CRC), but also likely of other specific types of cancer. Such specific cancer types are, e.g., esophagus, head and neck cancer, stomach cancer, bile duct cancer, pancreas cancer, kidney cancer, cervix cancer, ovary cancer, breast cancer, bladder cancer, endometrium cancer or prostate cancer. Furthermore, it especially relates to a method for assessing cancer from a liquid sample, derived from an individual by measuring seprase in said sample. Measurement of seprase can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.

The present invention provides a therapeutic agent for bile duct cancer comprising 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide or a pharmacologically acceptable salt thereof.

The present invention provides antibodies useful as therapeutics for treating and / or preventing diseases associated with cells expressing Claudin-6 (CLDN6), including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.

The present invention provides antibodies useful as therapeutics for treating and / or preventing diseases associated with cells expressing Claudin-6 (CLDN6), including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.

The invention belongs to the field of medicines, and relates to an application of a method for degrading all carbohydrate chains in the blood to be monosaccharide and detecting the monosaccharide in cancer detection. A sample in the method for degrading the blood to obtain the monosaccharide and detecting the monosaccharide is the blood, and the cancer includes lung cancer, gastric cancer, ovarian cancer, penis cancer, esophagus cancer, oral cancer, biliary duct cancer, breast cancer, adenocarcinoma perampullaire, rectal cancer and bladder cancer. The method has the characteristics of simplicity and easiness in operation steps, easiness in popularization, short detection time, low requirement on the instrument, low detection cost, less consumption of blood and the like. The result displays that based on the content of eight monosaccharides in the blood, not only can a normal person and a cancer patient be distinguished, but also different cancers can be distinguished. The method for simplifying glycomics knowledge and applying in the detection of the biomarker of blood is first created in the world.

Disclosed is a method aiding in the assessment of cancer. More specifically disclosed is the use of the arginine-rich metastasized in early tumors protein (=ARMET) as a universal marker of different cancer types. ARMET aids in the assessment of pulmonary or lung cancer (LC) or of colon cancer, e.g., of non-small cell lung carcinoma (NSCLC) or colorectal cancer (CRC), but also likely of other specific types of cancer. Such specific cancer types are, e.g., breast, ovary, cervix, head and neck, endometrium, melanoma, bladder, kidney, pancreas, prostate, esophagus, stomach or bile duct cancer. Further disclosed is a method for assessing cancer from a liquid sample, derived from an individual by measuring ARMET in the sample. Measurement of ARMET can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.

The present invention relates to methods and biomarkers (e.g., epigenetic biomarkers) for detection of gastrointestinal cancers (e.g., colorectal cancer, gastric cancer, pancreatic cancer, liver cancer, cancer of the gall bladder and / or bile ducts (e.g., cholangiocarcinoma)) in biological samples (e.g., tissue samples, stool samples, blood samples, plasma samples, cell samples, gall samples, bile samples, serum samples).

Disclosed is a method aiding in the assessment of cancer. More specifically disclosed is the use of the arginine-rich metastasized in early tumors protein (=ARMET) as a universal marker of different cancer types. ARMET aids in the assessment of pulmonary or lung cancer (LC) or of colon cancer, e.g., of non-small cell lung carcinoma (NSCLC) or colorectal cancer (CRC), but also likely of other specific types of cancer. Such specific cancer types are, e.g., breast, ovary, cervix, head and neck, endometrium, melanoma, bladder, kidney, pancreas, prostate, esophagus, stomach or bile duct cancer. Further disclosed is a method for assessing cancer from a liquid sample, derived from an individual by measuring ARMET in the sample. Measurement of ARMET can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.

The present invention relates to the use of a compound of formula 3 or a salt thereof to prepare a medicament or phototherapeutic agent for treating the following diseases, including: acne; AIDS; viral hepatitis; diabetic retinopathy; SARS virus infection; coronavirus Arterial stenosis; carotid artery stenosis; intermittent claudication; Asian (chicken) avian influenza virus infection; cervical dysplasia or various cancers, including: blood cancer, cervical cancer, nasopharyngeal cancer, tracheal cancer, laryngeal cancer, bronchial cancer , bronchiolar cancer, bladder cancer, esophageal cancer, stomach cancer, rectal cancer, colon cancer, prostate cancer, hollow organ cancer, bile duct cancer, urinary tract cancer, kidney cancer, uterine cancer, vaginal cancer and other gynecological adnexal cancer. The present invention also relates to methods of treating the above diseases. The present invention further relates to the use of the compound of formula 3 or a salt thereof to prepare a photodiagnostic agent for detecting the above-mentioned diseases and the following diseases, including: atherosclerosis, multiple sclerosis, diabetes, arthritis, rheumatism Arthritis, fungal infections, viral infections, chlamydial infections, bacterial infections, or parasitic diseases, HIV viral infections, hepatitis, herpes simplex, shingles, psoriasis, cardiovascular disease, and skin diseases. The present invention also relates to methods for detecting the above diseases using photodiagnostic agents. The present invention further relates to a method for low-temperature sterilization of surgical devices or other devices, including the steps of: providing a compound of Chemical Formula 3 or a salt thereof on the device; and subjecting the device to radiation treatment or sonication treatment. The invention further relates to a compound of formula 3 or a salt thereof linked or attached to a magnetic element. This compound acts as an MRI enhancer. The invention also relates to the use of such MRI enhancers for performing MRI scans.

The invention discloses a molecular marker-MARCO gene used for early diagnosis of bile duct cancer. Experiments show that mRNA level of the MARCO gene in bile duct cancer tissue is remarkably lower than that in normal bile duct tissue, so that whether a test receiver has risk of suffering from the bile duct cancer or not or whether the test receiver suffers from the bile duct cancer or not can be judged by measuring expression level of MARCO in the bile duct tissue of the test receiver. The MARCO gene and an expressed product thereof can be prepared to be drug to be used for patients suffering from the bile duct cancer or patients having high risk of suffering from the same to treat or prevent the bile duct cancer. A novel diagnosis method is provided for clinical diagnosis of the bile duct cancer, and novel candidate drug is provided for treating the bile duct cancer.

A duct stent being capable of carrying the subminiature radioactive particle source is mainly used for the inside radiation therapy of metaphase or terminal pancreatic cancer and bile duct cancer, and has drainage function. The duct stent consists of a tubular drainage tube (1) and fixation portions (2) which are face to face with two ends of the drainage tube (1) and can fix the stent to prevent the stent from moving. The lumen of the drainage tube (1) is a drainage cavity (1.1) for draining the pancreatic juice or the bile. A particle passage (1.2) is provided in the tube wall of the drainage tube (1). The inside diameter of the particle passage (1.2) matches with the outer diameter of the subminiature radioactive particle source.

The invention relates to the technical field of gene engineering, and particularly discloses a bile duct cancer prognosis determination marker, a detection primer, a kit and application, the bile ductcancer prognosis determination marker is 5 lncRNAs, and the 5 lncRNAs are respectively HULC, AP000943.4, AC006504.8, AC090114.2 and AL359715.5. A method comprises the following steps: constructing abile duct cancer data set; constructing an LncRNA and gene differential expression profile; establishing an LncRNA related prognosis prediction model; verifying and diagnosing an LncRNA related prognosis prediction model; performing survival prediction that the prognosis LncRNA marker is independent of other clinical pathological characteristic variables; and performing co-expression and functionenrichment analysis: the Spearman correlation coefficient being greater than 0.50 is DPCG related to the LncRNA.

The invention relates to application of degalactotigonin and a derivative thereof in preparation of an antitumor medicine. The nightshade Solanum Linn is extracted and separated from the compound. A pharmacological experiment proves that the degalactotigonin has high inhibition rate on tumor cells at a certain concentration; the anti-patent activity of degalactotigonin is obviously higher than that of a positive medicine 10-hydroxycamptothecine; the desgalactotigonin has relatively low toxicity on normal cells, and can be used for treating tumor diseases such as liver cancer, lung cancer, gastric cancer, colon cancer, breast cancer, ovarian cancer, oral cancer, esophagus cancer, bile duct cancer and leukemia. The invention further discloses a method for extracting degalactotigonin from plants. The method is simple and feasible, and has a good industrial prospect.

The invention belongs to the field of genetic engineering, and particularly relates to application of long-chain non-coding RNA and composition thereof to diagnosis and treatment of cancer of biliaryduct. Meanwhile, the invention further relates to application of a primer thereof to preparation of a reagent for diagnosing colon cancer. By studying the expression of the long-chain non-coding RNA cell, the relationship between the long-chain non-coding RNA and the pathogenesis of cancer of biliary duct is revealed.

The invention relates to a cancer and tumor eliminating external ointment. The cancer and tumor eliminating external ointment is mainly characterized in that 26 traditional Chinese medicines such as sixangular dysosma rhizome, the roots of red-rooted salvia, Manis pentadactyla and turtle shells are adopted for soaking and decocting with sesame oil to extract juice, the juice is mixed with 16 Chinese herbal medicine powder such as unprocessed semen strychni, radix aconite, asarum and ground beeltle to be uniform, and then yellow leads are added to obtain the cancer and tumor eliminating external ointment. The cancer and tumor eliminating external ointment has the effects of clearing away heat and toxic materials, resolving hard lumps, promoting blood circulation to remove blood stasis, breaking accumulation to relieve pain, inducing Ying heat into Qi phase, and warming Yang to remove obstruction and has the remarkable effect on treating esophagus cancer, gastric cancer, lung cancer, liver cancer, bile duct cancer, pancreatic cancer, bladder cancer, cervical cancer and brain cancer.

Described herein are antibodies and antibody fragments capable of treating or preventing cancers associated with the over-expression and / or up-regulation of DKK1. Also disclosed are methods of treating or preventing cancer using the antibody and methods and kits utilized to diagnosing cancer. The herein described products and methods find utility in the context of a variety of cancers, such as pancreatic cancer, gastric cancer, liver cancer, prostate cancer, breast cancer, cervical cancer, bile duct cancer, lung cancer and esophageal cancer.

The invention discloses metabolic markers for liver and gall disease diagnosis and a screening method thereof. The metabolic markers comprise a serum metabolic marker and a urine metabolic marker; theserum metabolic marker comprises one or any combination of EPA, AA, DHA, TCDA, DCA, GCA, TCA, GCDA, GCDCA, GDCA, CDCA, LPC16-0, LPC18-0, LPC18-1, LPC20-0. According to the screening method, a pre-established LC-MS / MS method is utilized to quantitatively detect the content of target metabolites in a clinical large sample (serum and urine), and a diagnostic marker is screened. The metabolic markerprovided by the invention can effectively diagnose liver and gall diseases, reduce the omission ratio of liver cancer and bile duct cancer, is very beneficial to early diagnosis and early treatment ofliver cancer and bile duct cancer, is greatly helpful for improving prognosis of liver cancer and bile duct cancer and reducing the mortality of liver cancer and bile duct cancer, and has good clinical application and popularization values. In practical application, more samples and more metabolite combinations can be selected for modeling according to the modeling method disclosed by the invention, so that the accuracy of the model is improved.

The present invention relates to a method for diagnosis of bile duct cancer, using methionyl-tRNA synthetase (MRS) in bile duct cells and, more particularly, to a composition for diagnosing bile ductcancer, comprising an agent with which an expression level of methionyl-tRNA synthetase protein is measured, a diagnostic kit, and a method for qualitative or quantitative analysis of MRS to provide information necessary for the diagnosis of bile duct cancer. According to the present invention, MRS retains a very high value as a diagnostic marker for bile duct cancer in terms of rapidity and accuracy because MRS allows determination to be made to see whether bile duct cancer is present or absent for bile duct cells, which have been classified as atypical cells by conventional pathological examination methods. Hence, the present invention provides a method for discriminating between cancer cells and normal cells in atypical cells and can make a definite diagnosis of cancer with almost 100 %in all of sensitivity, specificity, and accuracy in contrast to many conventional cancer markers with which an actual result of diagnosis is substantially difficult to obtain at a cell level (that is, cytodiagnosis).

The invention relates to a transplant for constructing a bile duct cancer xenograft model and a preparation method and application of the transplant. The preparation method comprises the steps that a,matrix glue and a bile duct cancer culture medium are mixed, and a bile duct cancer culture medium-matrix glue mixture is obtained; and b, mixing a bile duct cancer tissue subjected to enzymolysis with the bile duct cancer culture medium-matrix glue mixture, and carrying out culture amplification to obtain the transplant containing a bile duct cancer organoid. In the method, the bile duct cancertissue subjected to enzymolysis is cultured to obtain the transplant containing the bile duct cancer organoid, the success rate of constructing the bile duct cancer xenograft model by using the transplant is high, and the required time is short.

The invention provides an icariside I compound and a derivative and a pharmaceutical salt. A structure formula is shown as a formula I in the description. The compound, the derivative, the pharmaceutical salt or the composite is used for preparing medicine capable of being used for preventing, relieving or treating tumor diseases. The tumor includes liver cancer, lung cancer, colon cancer, ovariancancer, bile duct cancer, malignant lymphoma, liver cancer, bladder cancer and prostate cancer. The icariside I compound has obvious effects in aspects of improving the human immunity, improving thehuman IFN-gamma level, improving the apoptin NOXA expression and the like. Through in vivo experiments on mice and liver cancer cells (H22 cells and hepg2 cells) experiments, the results prove that the icariside I can obviously inhibit the tumor growth.

The invention discloses a blood extractor for bile duct cancer treatment and detection. The blood extractor comprises a mounting shell, a stable connection frame, a mounting base, a rotating base, a centrifugal radius adjusting assembly, a temporary storage bin and a blood test tube clamping mechanism, wherein the periphery of the mounting base is fixed in the mounting shell by adopting the stable connection frame, the rotating base is rotatably arranged on the mounting base, and the rotating action of the rotating base is controlled by a rotating driving assembly; and a centrifugal radius adjusting assembly is fixed above the rotating base, the centrifugal radius adjusting assembly at least comprises two adjusting ends, a temporary storage bin is fixed to each of the two adjusting ends, a mounting disc is fixedly communicated with the temporary storage bins, a plurality of blood test tube clamping mechanisms are mounted on the mounting disc in a circumferential array manner, the blood test tube clamping mechanisms are used for selectively clamping blood test tubes, and the adjusting end of each centrifugal radius adjusting assembly is independently adjusted, so that the centrifugal extraction degree of blood in different blood test tubes is changed.

The invention provides an extraction method and application of a tumor exosome vaccine. According to the invention, exosome is successfully extracted from the supernatant of a nutrient solution of human bile duct cancer cells, and an exosome lysis ultrafiltrate not containing miRNA is extracted by using an ultrafiltration lysis method. The exosome lysis ultrafiltrate not containing miRNA obtained in the invention can obviously stimulate immune cells to generate a specific tumor killing effect, greatly improve the killing effect, i.e., specific immune response, of the immune cells on a tumor, reduce the level of immune escape of tumor cells and enhance killing capability of the human immune cells on the tumor cells.

The present invention relates to a method aiding in the assessment of cancer. It discloses the use of the human fibroblast activation protein (FAP / seprase) as a universal marker of different cancer types. Seprase aids in the assessment of pulmonary or lung cancer (LC) or of colon cancer, e.g., of non-small cell lung carcinoma (NSCLC) or colorectal cancer (CRC), but also likely of other specific types of cancer. Such specific cancer types are, e.g., esophagus, head and neck cancer, stomach cancer, bile duct cancer, pancreas cancer, kidney cancer, cervix cancer, ovary cancer, breast cancer, bladder cancer, endometrium cancer or prostate cancer. Furthermore, it especially relates to a method for assessing cancer from a liquid sample, derived from an individual by measuring seprase in said sample. Measurement of seprase can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.

The present invention relates to vesicles derived from genus Morganella bacteria and a use thereof, the present inventors experimentally confirmed that the vesicles were significantly decreased in clinical samples derived from patients with a malignant disease such as gastric cancer, colorectal cancer, pancreatic cancer, bile duct cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer and lymphoma, a cardiovascular disease such as myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina, and stroke, diabetes mellitus, and Parkinson's disease as compared to normal persons, and the vesicles suppressed the secretion of inflammatory mediators by pathogenic vesicles and suppressed the occurrence of cancer, so that the vesicles derived from genus Morganella bacteria may be usefully used for the purpose of developing a method for diagnosing a malignant disease such as gastric cancer, colorectal cancer, pancreatic cancer, bile duct cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer and lymphoma, a cardiovascular disease such as myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina, and stroke, diabetes mellitus, and Parkinson's disease, and a composition for preventing or treating the diseases or an inflammatory disease